MA37739A1 - Composés et compositions destinés à la modulation de l'activité de l'egfr - Google Patents
Composés et compositions destinés à la modulation de l'activité de l'egfrInfo
- Publication number
- MA37739A1 MA37739A1 MA37739A MA37739A MA37739A1 MA 37739 A1 MA37739 A1 MA 37739A1 MA 37739 A MA37739 A MA 37739A MA 37739 A MA37739 A MA 37739A MA 37739 A1 MA37739 A1 MA 37739A1
- Authority
- MA
- Morocco
- Prior art keywords
- egfr
- compounds
- activity
- modulating
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Abstract
L'invention concerne des composés et leurs compositions pharmaceutiques, utiles pour la modulation de l'activité de l'egfr, ainsi que des procédés d'utilisation de tels composés pour traiter, améliorer ou prévenir une condition associée à une activité anormale ou dérégulée de l'egfr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1741DE2012 | 2012-06-06 | ||
PCT/US2013/044247 WO2013184757A1 (fr) | 2012-06-06 | 2013-06-05 | Composés et compositions destinés à la modulation de l'activité de l'egfr |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37739A1 true MA37739A1 (fr) | 2018-09-28 |
MA37739B1 MA37739B1 (fr) | 2018-10-31 |
Family
ID=54193706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37739A MA37739B1 (fr) | 2012-06-06 | 2013-06-05 | Composés et compositions destinés à la modulation de l'activité de l'egfr |
Country Status (42)
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI519515B (zh) | 2011-12-21 | 2016-02-01 | 諾維拉治療公司 | B型肝炎抗病毒劑 |
CA2868202C (fr) | 2012-04-03 | 2021-08-10 | Novartis Ag | Produits combines comprenant des inhibiteurs de tyrosine kinase et leur utilisation |
EA027280B1 (ru) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
JP2015526520A (ja) * | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Itk阻害剤としてのベンズイミダゾール誘導体 |
CA2899706C (fr) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyle-arylamides et utilisation connexe comme medicaments dans le traitement de l'hepatite b |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
BR112015028538A2 (pt) | 2013-05-17 | 2017-07-25 | Janssen Sciences Ireland Uc | derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b |
NO3024819T3 (fr) | 2013-07-25 | 2018-07-21 | ||
EP3049442A4 (fr) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
CA2923712C (fr) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Derives de carboxamide et leur utilisation en tant que medicaments pour le traitement de l'hepatite b |
WO2015081463A1 (fr) * | 2013-12-02 | 2015-06-11 | Novartis Ag | Formes d'inhibiteurs du recepteur du facteur de croissance epidermique (egfr) |
WO2015085482A1 (fr) * | 2013-12-10 | 2015-06-18 | Novartis Ag | Formes inhibitrices de l'egfr |
WO2015083059A1 (fr) * | 2013-12-02 | 2015-06-11 | Novartis Ag | Formes de l'inhibiteur du récepteur du facteur de croissance épidermique (egfr) |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
RU2702109C1 (ru) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Комбинированная терапия для лечения инфекций вгв |
CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
WO2015134210A1 (fr) * | 2014-03-03 | 2015-09-11 | Principia Biopharma, Inc. | Dérivés de benzimidazole en tant qu'inhibiteurs de rlk et itk |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
CA2943220C (fr) * | 2014-03-20 | 2024-01-16 | Capella Therapeutics, Inc. | Derives de benzimidazole comme inhibiteurs de tyrosine kinase de famille erbb pour le traitement du cancer |
US10202398B2 (en) | 2014-03-20 | 2019-02-12 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
WO2015145388A2 (fr) | 2014-03-27 | 2015-10-01 | Novartis Ag | Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt |
CA2954862A1 (fr) * | 2014-07-31 | 2016-02-04 | Novartis Ag | Polytherapie |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
WO2016055916A1 (fr) | 2014-10-06 | 2016-04-14 | Novartis Ag | Combinaison thérapeutique pour le traitement du cancer |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
TW201702232A (zh) | 2015-04-10 | 2017-01-16 | 亞瑞克西斯製藥公司 | 經取代之喹唑啉化合物及其使用方法 |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
CN108012529A (zh) * | 2015-05-15 | 2018-05-08 | 诺华股份有限公司 | 治疗egfr突变的癌症的方法 |
AU2016268477B2 (en) * | 2015-05-22 | 2018-12-20 | Novartis Ag | Pharmaceutical compositions |
WO2017004383A1 (fr) | 2015-06-30 | 2017-01-05 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
EP3316902A1 (fr) | 2015-07-29 | 2018-05-09 | Novartis AG | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
CN108235685A (zh) * | 2015-07-29 | 2018-06-29 | 诺华股份有限公司 | Pd-1拮抗剂与egfr抑制剂的组合 |
KR102650026B1 (ko) * | 2015-09-18 | 2024-03-22 | 메르크 파텐트 게엠베하 | Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도 |
US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058807A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
EP3356339A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
WO2017058915A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058768A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356328A1 (fr) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Formes cristallines d'un agent antiviral de l'hépatite b |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
JP7015059B2 (ja) | 2015-11-16 | 2022-02-15 | アラクセス ファーマ エルエルシー | 置換複素環式基を含む2-置換キナゾリン化合物およびその使用方法 |
CA3007671A1 (fr) | 2015-12-17 | 2017-06-22 | Novartis Ag | Molecules d'anticorps anti-pd-1 et leurs utilisations |
EP3440072B1 (fr) * | 2016-04-07 | 2020-01-29 | GlaxoSmithKline Intellectual Property Development Ltd | Amides hétérocycliques utiles en tant que modulateurs de protéine |
JP2019510795A (ja) * | 2016-04-08 | 2019-04-18 | ノバルティス アーゲー | 新規の治療的使用 |
EP3442524A2 (fr) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Associations et méthodes comprenant un inhibiteur d'ensemble capside |
US20170321285A1 (en) * | 2016-05-03 | 2017-11-09 | The Texas A&M University System | Nlrc5 as a biomarker for cancer patients and a target for cancer therapy |
EP3507367A4 (fr) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
CN107663170B (zh) * | 2016-07-29 | 2020-02-11 | 广东东阳光药业有限公司 | 制备贝西沙星中间体化合物的方法 |
CA2939286A1 (fr) * | 2016-08-17 | 2018-02-17 | Pharmascience Inc. | Spirocyclique contenant des composes et usages pharmaceutiques dudit spirocyclique |
EP3519402A1 (fr) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
WO2018140514A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573964A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018140513A1 (fr) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
CN106946779A (zh) * | 2017-02-13 | 2017-07-14 | 广州仁恒医药科技股份有限公司 | 一种r‑3‑氨基‑六氢氮杂*的制备方法 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CA3063440A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Inhibiteurs covalents de kras |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
WO2018218071A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Composés et leurs procédés d'utilisation pour le traitement du cancer |
WO2018237173A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes |
JP7433910B2 (ja) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Cd73に対する抗体分子及びその使用 |
WO2018234879A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | UTILISATION D'ANTICORPS DE LIAISON IL-1β DANS LE TRAITEMENT DU CANCER |
WO2018235056A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer |
US20200155566A1 (en) | 2017-08-03 | 2020-05-21 | Novartis Ag | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
SG11201913249SA (en) | 2017-08-03 | 2020-02-27 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
CN109721605B (zh) * | 2017-10-31 | 2022-03-11 | 维眸生物科技(上海)有限公司 | 一种免疫细胞迁徙抑制剂 |
KR20200096253A (ko) | 2017-11-30 | 2020-08-11 | 노파르티스 아게 | Bcma-표적화 키메라 항원 수용체, 및 이의 용도 |
EP3755694B1 (fr) | 2018-02-21 | 2023-04-05 | Boehringer Ingelheim International GmbH | Nouveaux composés de benzimidazole et dérivés en tant qu'inhibiteurs de l'egfr |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
JP7399872B2 (ja) | 2018-04-18 | 2023-12-18 | ノバルティス アーゲー | Cns転移の治療に使用するためのナザルチニブ |
UA126177C2 (uk) * | 2018-04-26 | 2022-08-25 | Пфайзер Інк. | Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
CN109369620B (zh) * | 2018-12-22 | 2020-04-14 | 山东大学 | 吡啶类化合物及其制备方法与抗胃癌应用 |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
JP2022538228A (ja) * | 2019-06-24 | 2022-09-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Egfr阻害剤としての新たな大環状化合物および誘導体 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
WO2021072475A1 (fr) * | 2019-10-15 | 2021-04-22 | Aucentra Therapeutics Pty Ltd | Dérivés de 4-(imidazo[1,2-a] pyridin-3-yl)-n-(pyridin-3-yl)pyrimidin-2-amine pour le traitement de maladies et d'affections prolifératives |
KR102267662B1 (ko) * | 2019-11-19 | 2021-06-22 | 한국화학연구원 | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
AU2021267213B2 (en) | 2020-05-08 | 2023-11-30 | Novartis Ag | Pharmaceutical combination comprising TNO155 and nazartinib |
JP2023526443A (ja) * | 2020-05-18 | 2023-06-21 | ウェルマーカー バイオ カンパニー リミテッド | Ron変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 |
KR20210142553A (ko) * | 2020-05-18 | 2021-11-25 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 |
US20230242521A1 (en) * | 2020-05-18 | 2023-08-03 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same |
US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
CN113880804A (zh) * | 2020-07-01 | 2022-01-04 | 微境生物医药科技(上海)有限公司 | 新型苯并咪唑化合物 |
WO2022081478A1 (fr) * | 2020-10-12 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs covalents du r-egf et leurs méthodes d'utilisation |
US20220133734A1 (en) | 2020-11-02 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
WO2022097060A1 (fr) | 2020-11-06 | 2022-05-12 | Novartis Ag | Molécules de liaison à cd19 et utilisations associées |
CN115368378A (zh) * | 2021-05-21 | 2022-11-22 | 深圳市塔吉瑞生物医药有限公司 | 取代的大环化合物及包含该化合物的组合物及其用途 |
EP4355330A1 (fr) | 2021-06-15 | 2024-04-24 | Genentech, Inc. | Inhibiteur d'egfr et activateur de perk en polythérapie et leur utilisation pour le traitement du cancer |
CA3235328A1 (fr) * | 2021-10-18 | 2023-04-27 | Jianwei Che | Inhibiteurs covalents d'egfr et leurs methodes d'utilisation |
KR102572664B1 (ko) * | 2022-02-07 | 2023-08-30 | 주식회사 인터엠 | 오디오 클록 조정 및 이를 이용한 네트워크 기반 전관 방송 |
WO2023209084A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques condensés et leur utilisation dans le traitement du cancer |
WO2023209090A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques et leur application dans le traitement du cancer |
US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
WO2023209088A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques et leur utilisation dans le traitement du cancer |
WO2023244587A1 (fr) * | 2022-06-14 | 2023-12-21 | Genzyme Corporation | Procédés de fabrication de tolébrutinib |
WO2024046221A1 (fr) * | 2022-09-02 | 2024-03-07 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Inhibiteurs d'egfr et leurs utilisations |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
EP1131425A2 (fr) | 1998-11-18 | 2001-09-12 | Incyte Pharmaceuticals, Inc. | Genes associes a des inflammations |
US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
ATE511840T1 (de) | 2001-10-09 | 2011-06-15 | Amgen Inc | Imidazolderivate als entzündungshemmende mittel |
KR20040063144A (ko) * | 2001-11-09 | 2004-07-12 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 단백질 키나제 억제제로서 유용한 벤즈이미다졸 |
WO2004014905A1 (fr) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes benzimidazole substitues |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
US20080146536A1 (en) | 2005-08-16 | 2008-06-19 | Pharmacopeia, Inc. | 2-Aminoimidazopyridines for treating neurodegenerative diseases |
CA2723961C (fr) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Derives phosphores servant d'inhibiteurs de kinase |
US20110294686A1 (en) | 2008-09-11 | 2011-12-01 | Drabkin Harry A | Egfr inhibitor therapy responsiveness |
US9150577B2 (en) | 2009-12-07 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing an indole core |
CN102134275B (zh) | 2010-01-26 | 2013-12-04 | 上海市肿瘤研究所 | 表皮生长因子受体变异体 |
WO2011099832A2 (fr) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant |
US8221644B2 (en) * | 2010-07-20 | 2012-07-17 | Miller Chemical & Fertilizer Corporation | Compositions and methods for anti-icing/de-icing |
KR20130108543A (ko) | 2010-08-05 | 2013-10-04 | 암젠 인코포레이션 | 역형성 림프종 키나제를 억제하는 벤즈이미다졸 및 아자벤즈이미다졸 화합물 |
US20150306086A1 (en) | 2011-11-14 | 2015-10-29 | Tesaro, Inc. | Modulating certain tyrosine kinases |
JP2015526520A (ja) | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Itk阻害剤としてのベンズイミダゾール誘導体 |
-
2013
- 2013-06-04 JO JOP/2013/0171A patent/JO3300B1/ar active
- 2013-06-05 PT PT137292199T patent/PT2773635T/pt unknown
- 2013-06-05 SI SI201330801T patent/SI2773635T1/sl unknown
- 2013-06-05 PE PE2014002377A patent/PE20150726A1/es active IP Right Grant
- 2013-06-05 MX MX2014014961A patent/MX345630B/es active IP Right Grant
- 2013-06-05 RS RS20170954A patent/RS56396B1/sr unknown
- 2013-06-05 SG SG11201407793TA patent/SG11201407793TA/en unknown
- 2013-06-05 UY UY0001034849A patent/UY34849A/es active IP Right Grant
- 2013-06-05 UA UAA201412612A patent/UA113543C2/uk unknown
- 2013-06-05 NZ NZ627661A patent/NZ627661A/en unknown
- 2013-06-05 JP JP2015516156A patent/JP6039800B2/ja active Active
- 2013-06-05 HU HUE13729219A patent/HUE034759T2/en unknown
- 2013-06-05 MY MYPI2014003216A patent/MY165036A/en unknown
- 2013-06-05 KR KR1020147037047A patent/KR101817829B1/ko active IP Right Grant
- 2013-06-05 BR BR112014030386-0A patent/BR112014030386B1/pt active IP Right Grant
- 2013-06-05 US US14/405,773 patent/US9440957B2/en active Active
- 2013-06-05 EP EP13729219.9A patent/EP2773635B1/fr active Active
- 2013-06-05 ES ES13729219.9T patent/ES2645973T3/es active Active
- 2013-06-05 TW TW102119989A patent/TWI650319B/zh active
- 2013-06-05 DK DK13729219.9T patent/DK2773635T3/da active
- 2013-06-05 GE GEAP201313656A patent/GEP201606555B/en unknown
- 2013-06-05 PL PL13729219T patent/PL2773635T3/pl unknown
- 2013-06-05 EA EA201492219A patent/EA026269B1/ru not_active IP Right Cessation
- 2013-06-05 MA MA37739A patent/MA37739B1/fr unknown
- 2013-06-05 CA CA2875966A patent/CA2875966C/fr active Active
- 2013-06-05 CN CN201380029790.XA patent/CN104379575B/zh active Active
- 2013-06-05 WO PCT/US2013/044247 patent/WO2013184757A1/fr active Application Filing
- 2013-06-05 AP AP2014008083A patent/AP3909A/en active
- 2013-06-05 LT LTEP13729219.9T patent/LT2773635T/lt unknown
- 2013-06-05 AU AU2013271733A patent/AU2013271733B2/en active Active
- 2013-06-05 EP EP17176482.2A patent/EP3257848A1/fr not_active Withdrawn
- 2013-06-06 AR ARP130101989 patent/AR091368A1/es active IP Right Grant
-
2014
- 2014-11-21 TN TN2014000487A patent/TN2014000487A1/fr unknown
- 2014-11-27 IL IL235974A patent/IL235974A/en active IP Right Grant
- 2014-11-27 CL CL2014003227A patent/CL2014003227A1/es unknown
- 2014-12-02 DO DO2014000277A patent/DOP2014000277A/es unknown
- 2014-12-03 PH PH12014502704A patent/PH12014502704B1/en unknown
- 2014-12-05 CO CO14268955A patent/CO7160047A2/es unknown
- 2014-12-05 GT GT201400282A patent/GT201400282A/es unknown
- 2014-12-05 CR CR20140563A patent/CR20140563A/es unknown
- 2014-12-05 CU CUP2014000139A patent/CU20140139A7/es unknown
-
2017
- 2017-10-31 HR HRP20171670TT patent/HRP20171670T1/hr unknown
- 2017-11-02 CY CY20171101147T patent/CY1119531T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37739B1 (fr) | Composés et compositions destinés à la modulation de l'activité de l'egfr | |
MA34948B1 (fr) | Composes et procedes de modulation de kinase, et leurs indications | |
MA35460B1 (fr) | Composés et compositions en tant qu'inhibiteurs de kinase c-kit | |
MA40290A1 (fr) | Agents immunorégulateurs | |
MA34969B1 (fr) | Composes et compositions en tant qu inibiteurs de trk | |
MA43186B1 (fr) | Anticorps se liant spécifiquement à pd-1 et leurs utilisations | |
BR112015001613A2 (pt) | compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx | |
MA38554A3 (fr) | Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation | |
MA38341B1 (fr) | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées | |
MA37538B1 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
BR112014028991A2 (pt) | triazóis como inibidores de kv3 | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
MA41988A (fr) | Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa | |
MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
MA33457B1 (fr) | L-sérine pour son utilisation en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau | |
MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
FR3038605B1 (fr) | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation | |
MA40289A1 (fr) | Agents immunorégulateurs | |
MA37966B1 (fr) | Utilisation de venins d'araignées pour le blanchiment/la dépigmentation de la peau et composition comprenant des molécules de venins d'araignées ou des analogues synthétiques | |
MA39354A1 (fr) | Compositions et procédés pour moduler l'expression du facteur b du complément |